Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367301 · ClinicalTrials.gov registry record · NA
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
A NA study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01367301 is a NA study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 14 participants.
The verdict
NCT01367301, a NA study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving radiation with chemotherapy may kill more tumor cells.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION intensity-modulated radiation therapy
- RADIATION brachytherapy
- RADIATION external beam radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-07-08 |
| Est. Completion | 2018-08-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01367301
The ClinicalTrials.gov registry entry for NCT01367301 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT01367301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01367301 about?
NCT01367301 is a clinical study titled "Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer". This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor...
What is the current status of trial NCT01367301?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2011-07-08. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT01367301?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), intensity-modulated radiation therapy (RADIATION), brachytherapy (RADIATION), external beam radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01367301?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.